SGLT2 inhibitors in frailty: a review of current evidence, and clinical recommendations
British Journal of Cardiology · 2026
DOI: 10.5837/bjc.2026.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Cardiology, 2026. Verfasst von Milo Simpson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Education Fellow, University Hospitals Sussex NHS Foundation Trust. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Education Fellow, University Hospitals Sussex NHS Foundation Trust.
- ICU Clinical Fellow, University College London Hospitals NHS Foundation Trust.
- Diabetes and Endocrine Specialty Trainee, University Hospitals Sussex NHS Foundation Trust.
- Academic Clinical Lecturer in Cardiology, University of Leicester, Leicester.
- Consultant Cardiologist and Associate Professor, Rio de Janeiro State University, Rio de Janeiro, Brazil.
- Honorary Senior Lecturer (Diabetes and Endocrinology), Bangor University, Bangor.
Zitieren
APA
Simpson, M., Datta, S., Golding, J., Gulsin, G., Kaiser, S., & Puttanna, A. (2026). SGLT2 inhibitors in frailty: a review of current evidence, and clinical recommendations. British Journal of Cardiology. https://doi.org/10.5837/bjc.2026.002
Vancouver
Simpson M, Datta S, Golding J, Gulsin G, Kaiser S, Puttanna A. SGLT2 inhibitors in frailty: a review of current evidence, and clinical recommendations. British Journal of Cardiology. 2026. doi:10.5837/bjc.2026.002
BibTeX
@article{Simpson2026,
author = {Simpson, Milo and Datta, Shayan and Golding, Jonathan and Gulsin, Gaurav and Kaiser, Sergio and Puttanna, Amar},
title = {SGLT2 inhibitors in frailty: a review of current evidence, and clinical recommendations},
journal = {British Journal of Cardiology},
year = {2026},
doi = {10.5837/bjc.2026.002}
}
EUVIMED